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Abstract  34 
Context: Uterine quiescence must be maintained until pregnancy reaches term. Premature activation 35 
of myometrial contractility leads to preterm labour and delivery.  36 
Objective: To scrutinise the potential of androgens to relax the myometrium and the mechanism of 37 
their action. 38 
Samples: A pregnancy-derived myometrial smooth muscle cell line (PHM1-41), myometrial strips 39 
prepared from tissues obtained from pregnant women [lean (n=9) and obese (n=6)] undergoing 40 
elective C-section at term and from non-pregnant C57BL/6 mice (n=5) were each utilised. 41 
Design: The contraction of collagen-embedded PHM1-41s and the stretch-induced contraction of 42 
human and murine myometrial strips were assessed following incubation with testosterone (T), 43 
dihydrotestosterone (DHT) and T conjugated to BSA (TBSA). Intracellular calcium ([Ca2+]) and 44 
phosphorylated myosin light chain (PMLC) concentrations were quantified in PHM1-41s using a 45 
Fluo-4 Ca2+ assay and in-cell Westerns (ICW) respectively. 46 
Setting: University Research Institute. 47 
Results: DHT and T, but not TBSA, impaired the contractile function of PHM1-41s and of human and 48 
murine myometrial strips. The response was rapid (observed within minutes), sustainable for up to 48 49 
hours, and not abolished on knockdown of the androgen receptor (AR). DHT (100 μM) reduced the 50 
amplitude of lean strip contraction to 2%±2 of the pre-treatment value and T (100 μM) to 3.3%±1. 51 
These values for obese strips were 15%±6.7 and 11%±6.7 respectively. At the same doses, in murine 52 
strips, DHT reduced the amplitude to 4.8%±3 and T to 4.9%±3. DHT (50 μM) pre-treatment reduced 53 
the OXT-stimulated increase in [Ca2+] (p<0.0001, n=6) and PMLC (p<0.05, n=5) in PHM1-41s.     54 
Conclusion: Lipid soluble androgens could be developed as tocolytic agents for the treatment of 55 
preterm labour.   56 
 4 
Introduction 57 
Preterm birth (PTB), defined as birth before 37 weeks of pregnancy, accounts for 5-18% of all 58 
recorded births worldwide (1). Importantly, PTB is associated with long-term neurodevelopmental 59 
outcomes and an increased risk for respiratory and gastrointestinal complications in the offspring (2). 60 
The major obstetric precursor leading to PTB is spontaneous preterm labour, the outcome of preterm 61 
onset of regular myometrial contractions. The first line management of threatened PTB is initiation of 62 
tocolytic medications to suppress these contractions. Their mode of action is gene-transcription 63 
independent and involves rapid inhibition of key components in the contraction cascade, for example 64 
the oxytocin receptor (OXTR) and the various calcium (Ca2+) channels (3). Tocolytics reduce the 65 
availability of intracellular Ca2+ ([Ca2+]), prevent the phosphorylation of myosin light chain (MLC) 66 
and, thereby, the synchronised contraction of the myometrium. The currently used short-term tocolytic 67 
agents, such as Nifedipine, an L-type Ca2+ channel blocker, and OXTR antagonists, have high 68 
tocolytic efficacy in the short term, but their lack of longer term effect limits their effect on perinatal 69 
mortality (4,5). Conversely, magnesium sulfate - an inhibitor of MLC phosphorylation – which is the 70 
most commonly used tocolytic in the USA, is associated with maternal side effects and has low 71 
tocolytic efficacy (6).  72 
Steroid hormones are currently the focus of much interest for PTB treatment and prevention. 73 
Prophylactic administration of vaginal progesterone (P) to pregnant women at high risk has been 74 
shown to reduce the rate of PTB by 50% (7). Our research group has previously demonstrated that 75 
exposure of spontaneously contracting myometrial strips to progesterone (P) resulted in a rapid (<30 76 
minutes) reduction in the amplitude and integral of contraction, in line with P’s well-established role 77 
in maintenance of pregnancy (8). In addition to P, one study reported that androgens in micromolar 78 
doses also relaxed human myometrial contractions ex vivo (9). We have recently reviewed all the 79 
evidence for a role of androgens in maintenance of pregnancy (10). Considering that a) tocolytics in 80 
current use delay delivery only by 24 hours to 7 days, b) P supplementation prevents only one-third of 81 
all recurrent PTBs and finally c) androgens produced by the placenta could be involved in the 82 
maintenance of pregnancy, we hypothesised that androgens should be investigated as novel PTB 83 
therapeutic agents. However, there is limited evidence on the efficacy of androgens, and the 84 
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mechanism of action of androgens in preventing uterine contractions is poorly understood. Herein, we 85 
sought to address the effects of androgens on myometrial contractions and explore how they interact 86 
with the contractile apparatus. Specifically, we aimed to deduce a) whether T, dihydrotestosterone 87 
(DHT; non-aromatisable metabolite of T) and the cell-surface impermeable T (TBSA) inhibit the 88 
contraction of uterine myocytes in vitro and ex vivo in both human and mouse and b) to test the 89 
hypothesis that androgens prevent uterine contractions via reduction in the concentration of [Ca2+] 90 
and, hence, reduction in the phosphorylation of MLC.  91 
Materials and Methods 92 
Human Tissue 93 
Biopsies were obtained from the upper margin of the lower segment of myometrium from women 94 
undergoing elective caesarean section (ECS) as previously described (11) at the Simpson’s Centre for 95 
Reproductive Health at the Royal Infirmary of Edinburgh, following informed written consent. Ethics 96 
approval for recruitment of all pregnant women was granted by the West of Scotland Research Ethics 97 
Committee 4 (09/S0704/3) to the Edinburgh Reproductive Tissue BioBank. Biopsies were collected 98 
from lean (LN; 19<BMI<25) and obese (OB; BMI>25) women delivering at term (>37 weeks of 99 
gestation) prior to the onset of labour. Patients with twin pregnancies and pregnancy complications 100 
were excluded. The recovered biopsies were collected in ice-cold Rosewell Park Memorial Institute 101 
1640 medium (RPMI; Gibco), rinsed in PBS and dissected into 2x2x15 mm strips parallel to the 102 
muscle fibre bundles.  103 
Mouse Tissue 104 
Experimental procedures were licensed (PPL 60/4241; PIL 60/13875) under the UK Home office 105 
Animals (Scientific Procedures) Act (1986). Murine uterine horns were harvested from 8-week old 106 
non-pregnant C57BL/6 mice supplied by Charles River (London, UK) and prepared into uterine strips 107 
(1 cm long each). 108 
Human Uterine Myocytes 109 
Pregnant human myometrial 1-41 (PHM1-41) cells were obtained from a single late-term pregnant 110 
donor as previously described (12). PHM1-41s were cultured as detailed elsewhere (13,14) with the 111 
exception that we used phenol red-free high-glucose Dulbecco's modified Eagle's medium (DMEM; 112 
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Lonza, UK). A PHM1-41 cell line in which the AR had been silenced (hAR-PHM1-41s) was produced 113 
using microRNA lentivirus. A scramble microRNA lentivirus (in which the AR remained active) was 114 
used as a negative control (Scr-PHM1-41s) as detailed in Supplemental Data and shown in 115 
Supplemental Figure 2.  116 
Experimental compounds 117 
DHT, T, Nifedipine, T3-(O-carboxymethyl)oxime:BSA (TBSA) were purchased from Sigma (Poole, 118 
UK) and oxytocin (OXT) from Alliance Pharmaceuticals (Chippenham, UK). DHT and T were 119 
reconstituted in ethanol (etOH), Nifedipine in DMSO and OXT was diluted in dH2O. TBSA, with 120 
conjugation ratio T (30 molecules):BSA (1 molecule), was reconstituted in PBS. Anti-Phosphorylated 121 
Myosin Light Chain (PMLC) polyclonal antibody (Cell Signaling, UK) was used in 1:50, anti-α-122 
Tubulin monoclonal antibody (Sigma) in 1:1000 and secondary antibodies 800CW and 680RD in 123 
1:10000 (Li-Cor Biosciences, UK).  124 
Organ bath  125 
The assessment of myometrial contractility utilising organ bath is well established (8,13,15,16). 126 
Briefly, human myometrial and mouse uterine strips were attached by silk suture (Mersilk 3-0, 127 
Ethicon Inc) to a force transducer (ML0186/10 Panlab ADInstruments, UK) and stretched under 128 
passive resting tension (20 mN) in Krebs buffer (115 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 129 
1.2 mM NaH2PO4, 1.2 mM Na2SO4, 2.5 mM CaCl2, 25 mM NaHCO3, 10 mM Glucose, pH 7.4) 130 
equilibrated with 95% O2-5% CO2 at 37°C. Strips were allowed an equilibration period of 2 hours to 131 
develop spontaneous rhythmic contractile activity before addition of DHT or T in cumulative 132 
concentrations (10 μM to 100 μM) or TBSA (0.5 μΜ equivalent to 100 μM dose of T). Each treatment 133 
was applied for 30 minutes for human tissue and 10 minutes for mouse. Equivalent doses of vehicle 134 
(etOH or PBS) were applied; the minimum and maximum concentration of etOH used was 0.03% and 135 
0.3% respectively. At the end of each experiment, the strips were stimulated with KCl (55 mM) and 136 
washed with fresh Krebs buffer to verify tissue viability/recovery. Data was recorded with LabChart 7 137 
acquisition software (AD Instruments). The average frequency, peak amplitude and force integral 138 
(area under curve; A.U.C.) following each treatment were calculated for each strip as a percentage of 139 
its pre-treatment values. 140 
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Gel contraction assay 141 
Cells were embedded in type I collagen in 24-well plates at 105 cells/well as previously described 142 
(13,14). Briefly, the collagen/cell suspension was allowed to polymerise and the gels were detached 143 
and incubated at 37oC for 24 and 48 hours with treatments prepared in 5% (v/v) charcoal-stripped fetal 144 
bovine serum (FBS) DMEM. Untreated or vehicle-treated cells developed a basal contraction, which 145 
manifested as a decrease in the gel area and was first evident 24 hours post detachment. The gels were 146 
photographed using a Leica MZ6 light microscope/camera (Mayfair, UK) at 0, 24 and 48 hours. 147 
Adobe Photoshop CS6 (CA, USA) was used to measure gel area. The measurement (pixels) for each 148 
gel area at 24 and 48 hours was reported as a percentage of the gel area at the 0-hour time point. The 149 
viability of cells in gels was assessed using CellTitre 96 AQueousOne Solution Cell Proliferation 150 
Assay kit (Promega, UK).  151 
In-cell Western (ICW) blot analyses 152 
Due to the rapid oscillations between the phosphorylated and dephosphorylated states of MLC and in 153 
order to accurately capture the cell transient contractile state, we utilised ICW, to quantify PMLC in 154 
PHM1-41s as described elsewhere (13,17). Briefly, cells were seeded into black-wall/optically clear-155 
bottom tissue culture treated 96-well plates (PerkinElmer) to a concentration of 1.8x104 cells/well in 156 
charcoal-stripped 5% (v/v) FBS DMEM. Following application of treatments, cells were fixed in 157 
3.7% (v/v) formaldehyde (Sigma) and incubated with primary and secondary antibodies. The plate 158 
was scanned using the Li-Cor Odyssey Infrared Imaging System (Li-Cor Biosciences). The intensity 159 
of PMLC fluorescence was calculated relative to α-Tubulin in the same well. 160 
Calcium assay 161 
The BDTM Calcium Assay Kit (BD Biosciences) was employed to measure [Ca2+] concentration in 162 
PHM1-41s. The assay was performed as described in Li et al (18). Briefly, PHM1-41s were seeded in 163 
white 96-well plates with a clear bottom (Perkin Elmer) in charcoal stripped 5% (v/v) FBS DMEM at 164 
a density of 3x104 cells/well. Following attachment, the cells were first incubated with the Ca2+ 165 
indicator, and then treated with DHT or vehicle (etOH). The plates were placed onto a fluorometric 166 
imaging plate reader (FLIRP)-NOVOstar (BMG Labtech, Germany) with built-in injectors. Prior to 167 
the injection of a compound, the basal cellular fluorescence, which denoted the concentration of 168 
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[Ca2+], was recorded for 20 seconds using the MARS Data Analysis Software (BMG Labtech). 169 
Following injection, the changes in the fluorescence were recorded for 40 seconds. The readout was 170 
the highest fluorescence measurement recorded (peak) following injection and that was compared 171 
between treatments.  172 
Statistics 173 
All analysis was conducted with GraphPad Prism v6.0 (La Jolla, USA). For human and mouse, n 174 
represents the number of individual patients or mice. For cells studies, the n number denotes the 175 
number of times the experiment was repeated and the number of replicates per experiment is indicated 176 
in the figure legends. For statistical analysis, all percentage-presented data were arcsine-transformed. 177 
Data was analysed as indicated in the figure legends and presented as the mean ± SEM; p<0.05 was 178 
considered statistically significant. 179 
Results  180 
Androgens inhibit the contraction of uterine myocytes embedded in collagen gels 181 
We set out to explore the effect of lipid soluble androgens DHT and T and of the cell-impermeable 182 
TBSA on the contraction of PHM1-41s cells. PHM1-41 cells were embedded in gels and incubated 183 
with vehicle (etOH), DHT or T (1 μM, 50 μΜ, 100 μΜ) or TBSA (0.5 μΜ) for 24 and 48 hours. Over 184 
time, vehicle gels developed a basal contraction resulting in a decrease in the gel area (Figure 1A). At 185 
24 hours, the vehicle area was 77.2%±3.4 of the original (measured at 0 hours) (Figure 1B) and at 48 186 
hours the area decreased to 65.2%±3.8 (Figure 1C). In contrast, the gel area of cells treated with DHT 187 
and T at 50 μΜ and 100 μΜ (Figure 1A), but not 1 μΜ, was significantly greater compared to the 188 
time-matched vehicle gel area, suggesting that both androgens prevented basal contraction. At 24 189 
hours, the DHT (100 μM) gel area was 95.8%±1.2 (p<0.0001 vs vehicle) of the area recorded at 0 190 
hours (Figure 1B) and 82%±6.4 (p<0.05 vs vehicle) at 48 hours (Figure 1C). For T (100 μM), these 191 
values were 94.9%±1.1 (p<0.001 vs vehicle) at 24 hours (Figure 1B) and 87.72%±5.5 (p<0.001 vs 192 
vehicle) at 48 hours (Figure 1C). TBSA treatment (Figure 1D) did not prevent basal contraction at 24 193 
(Figure 1E) and 48 hours (Figure 1F), suggesting that the T-mediated inhibition of contraction is 194 
unlikely to be cell-surface receptor mediated. In addition, the finding that DHT (50 μM) prevented the 195 
basal contraction of PHM1-41s in which expression of the AR was silenced (hAR-PHM1-41s; Figure 196 
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1 G, H) suggested that AR is unlikely to be involved in the induction of relaxation by androgens. 197 
Finally, a viability assay ruled out the hypothesis that androgens at high micromolar doses induce cell 198 
death (Figure 1I). We conclude that long (>24 hours) exposure to lipid soluble androgens can inhibit 199 
uterine smooth muscle contraction in vitro via an AR-independent mechanism that is likely to be 200 
mediated by penetration through the cell membrane.  201 
Androgens relax human and mouse uterine smooth muscle ex vivo 202 
We examined the effect of short-term (<6 hours) exposure of androgens on spontaneous contractions 203 
of LN and OB human (Figure 2) and mouse (Figure 3) myometrium. Cumulative doses of DHT and 204 
T were applied onto human myometrial (Figure 2A) and murine uterine strips (Figure 3A) all 205 
contracting in organ bath chambers. Progressive significant reductions in average amplitude and 206 
A.U.C. were observed as the dose of T or DHT was increased from 10 μM to 100 μΜ for human (LN: 207 
Figure 2B, D; OB: Figure 2F, H) and murine (Figure 3B, D) tissue. Only at the 100 μM dose, the 208 
frequency of contraction significantly decreased following treatment with DHT and T for LN 209 
(Figure 2C), OB (Figure 2G) and murine (Figure 2C) tissue. In order to inform future in vivo 210 
experiments, we calculated the IC50 values of DHT and T on amplitude and A.U.C. of contraction 211 
(Table 1). The IC50 values were not significantly different between the OB and LN groups and 212 
between human and mouse tissue. Contractions of myometrial strips were not affected by TBSA 213 
(0.5 μM) in human  (LN: Figure 2E, OB: Figure 2I) or mouse (Figure 3E).  214 
The organ bath studies combined with the gel contraction studies allowed the observation that lipid 215 
soluble androgens induce a rapid but sustained inhibition of uterine contractions. 216 
Androgens inhibit MLC phosphorylation in uterine myocytes  217 
Elevation in [Ca2+] activates the Ca2+ sensor calmodulin, which binds to MLC kinase, activating MLC 218 
phosphorylation and subsequent contraction. We aimed to deduce whether DHT treatment prevented 219 
the phosphorylation of MLC (PMLC) in contracting PHM1-41s. OXT was utilised to stimulate 220 
contraction of collagen embedded-PHM1-41s. A 24- and 48-hour treatment with OXT enhanced 221 
contraction, which manifested as a decrease in gel area, with the area being smaller than that of 222 
vehicle (Figure 4A). After 24 hours (Figure 4B) the average vehicle gel area was 83.4%±6.9 of the 223 
original gel area (measured at 0 hours) and it was significantly different (p<0.001) when compared to 224 
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the time-matched OXT gel area (66%±1.9). The co-treated OXT+DHT gel area was 82.8%±2.8 and 225 
significantly bigger than that the OXT gel area (p<0.01), demonstrating that DHT prevented the OXT-226 
stimulated contraction (Figure 4B). The co-treated OXT+DHT gel area reduced to 78.2%±1.2 after 48 227 
hours (Figure 4C) and was significantly different (p<0.0001) to the time-matched OXT gel area 228 
(42.2%±3.7).  229 
To determine whether the effect of DHT involved blockade of MLC phosphorylation, we assessed the 230 
impact of DHT pre-treatment on PMLC concentration following acute (30 seconds) stimulation with 231 
OXT. Acute stimulation with OXT induced a dramatic increase (p<0.001) in the concentration of 232 
fluorescently-detected PMLC and a short (15 minutes) pre-incubation with DHT, but not vehicle, 233 
significantly (p<0.05) prevented the increase in PMLC following acute OXT (Figure 4E). 234 
Interestingly, pre-incubation with a Ca2+ channel blocker Nifedipine, prior to acute OXT, also 235 
significantly (p<0.01) prevented the increase in PMLC concentration (Figure 4G). We conclude that 236 
DHT inhibits PHM1-41s contraction via inhibition of MLC phosphorylation. The similarity between 237 
the actions of DHT and the L-type Ca2+ channel blocker Nifedipine with regards to prevention of 238 
MLC phosphorylation, contributes to the notion of an indirect effect of DHT on PMLC, potentially 239 
mediated via blockade of Ca2+ channels and subsequent decrease in [Ca2+].  240 
Androgens inhibit Ca2+ flux in uterine myocytes  241 
We set to explore the hypothesis that DHT pre-treatment would prevent the increase in [Ca2+] 242 
concentration in PHM1-41s. OXT was used to stimulate a rapid increase in [Ca2+] concentration. 243 
Addition of OXT to untreated PHM1-41s induced an immediate 2-fold increase above baseline 244 
(p<0.0001) in the concentration of [Ca2+] (Figure 5B). The effect of OXT on [Ca2+] was examined 245 
following pre-treatment with either DHT or vehicle. DHT pre-treatment induced a dose-dependent 246 
reduction in the OXT-stimulated increase in [Ca2+], which was significant when compared to the 247 
OXT-stimulated increase in [Ca2+] in the vehicle pre-treated cells (Figure 5B, C, D). These data 248 
suggest that DHT blocks Ca2+ flux in uterine myocytes and impacts downstream MLC 249 
phosphorylation.  250 
Discussion 251 
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A relaxant effect of androgens on smooth muscle contraction has been reported in different systems 252 
(19-23). Ten years ago, a single study demonstrated that various androgens, including DHT and T, 253 
relaxed human myometrial strips contracting under resting tension in organ bath chambers (9). The 254 
authors described the response as rapid (minutes), transcription independent (not prevented by protein 255 
synthesis inhibitors), achievable with pharmacological (micromolar) doses, and as reversible. Herein 256 
we show for the first time that a) only lipid soluble androgens (T, DHT) effectively relax obese and 257 
lean human and murine myometrial contractions, b) the response is immediate (minutes) but can be 258 
sustained for longer times (days) even in the presence of cell viability, c) the mechanism of relaxation 259 
is a reduction in the availability of [Ca2+] concentration, which subsequently results in reduction of 260 
MLC phosphorylation in the uterine myocytes and, finally d) the mechanism of relaxation is AR-261 
independent.   262 
Other studies have reported the effects of sex hormones on [Ca2+] and PMLC concentrations in other 263 
cell types and tissues. For example, DHT treatment of Fura-2-loaded isolated rat vas deferens cells 264 
blunted the KCl-induced elevation in [Ca2+], while short incubation with estradiol (E2) inhibited the 265 
histamine-induced increase in [Ca2+] in Fura-2-loaded airway smooth muscle (ASM) cells (24,25). 266 
These findings are in line with the inhibitory effect of DHT on OXT-stimulated increase in [Ca2+] 267 
concentration in Fura-4-loaded PHM1-41s in our study. Consistent with our finding that DHT blunted 268 
the effect of OXT on PMLC, incubation with E2 and P in micromolar doses inhibited increases in 269 
PMLC in retinal epithelial and colon muscle cells (26,27).   270 
It is reasonable to speculate that androgens restrict Ca2+ flux in uterine myocytes. Such an effect can 271 
be achieved either by physical interaction with Ca2+ channels or indirectly by interaction with 272 
molecules residing on the cell membrane, which are known to regulate Ca2+ channel activity (28). A 273 
physical interaction of androgens with Ca2+ channels has never been described but there is some 274 
evidence to support an indirect effect of androgens on Ca2+ channels. The antagonism of OXT by DHT 275 
observed in our study might suggest that androgens interact with the mechanism by which OXTR 276 
signalling activates capacitive and non-capacitive Ca2+ entry in PHM1-41s (29). The binding of OXT 277 
to OXTR, a G protein-coupled receptor, activates transmembrane receptor operated Ca2+ channels 278 
(ROCCs) to induce Ca2+ flux from the extracellular space into the cell but can also stimulate the IP3 279 
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cascade, which results in the activation of IP3 receptors on the sarcoplasmic reticulum (SR) and 280 
release of Ca2+ from the internal store into the cytoplasm (28,30). Therefore, it is plausible that DHT 281 
blocked either the ROCCs-associated pathway or the downstream activators of the IP3 pathway, 282 
which manifested as a decrease in total concentration of [Ca2+] in PHM1-41s. However, evidence from 283 
a coronary muscle study, where T failed to inhibit caffeine- and carbachol-induced (activators of IP3-284 
pathway) Ca2+ release from the SR, suggests that androgens are likely to block the ROCCs-associated 285 
Ca2+ flux rather than the IP3 pathway (31). We hypothesise two mechanisms by which androgens 286 
could decrease the ROCCs-associated Ca2+ flux: a) Bind to a cell surface-associated binding protein 287 
that interacts with the OXTR and induce conformational changes to the receptor, which could result in 288 
impaired interaction of OXTR with the G-protein or b) overload the plasma membrane and change 289 
membrane fluidity, which could prevent the OXTR from interacting with the G-protein. Notably, if a 290 
membrane-initiated response were to mediate the effect of T in the myometrium, TBSA would be 291 
expected to inhibit the myometrial contractions in our study. However, TBSA did not induce 292 
relaxation, suggesting that the action of T is unlikely to be mediated via cell-surface receptors but 293 
requires penetration into, or through, the cell membrane. Therefore, it is possible that penetration of 294 
hydrophobic androgens into the negatively charged lipid bilayer altered the contractile function of 295 
PHM1-41s via impairment of cell membrane fluidity, which is known to affect active and passive 296 
transport of various molecules (32). The mechanism by which OXTR causes the opening of ROCCs is 297 
not clear (33), however, understanding this mechanism would help determine how androgens interact 298 
with the contractile cascades and inform whether they could be utilised as alternative tocolytics.  299 
It is noteworthy that Nifedipine’s uterorelaxant effect comes to prominence within 20 minutes of 300 
administration to pregnant women presenting with preterm contractions, and the impact of a single 301 
dose can last for up to 6 hours (34). The rapid response of myometrium to Nifedipine resembles the 302 
immediate (minutes) response to androgens observed in our study ex vivo in the term and possibly 303 
preterm (Supplemental Figure 1) myometrium. Adding to the similarity noted between the two 304 
responses, we showed that short incubations with DHT or Nifedipine each reduced the OXT-305 
stimulated PMLC in PHM1-41s, suggesting that both compounds can rapidly manipulate components 306 
of the contractile apparatus.  307 
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With the aim of decreasing maternal and fetal side effects during tocolysis and delaying pregnancy 308 
until term, there is growing interest in the discovery and validation of alternative tocolytics. The 309 
benefits and harms of supplemental P, which inhibits human myometrial contraction with similar 310 
IC50s (16) to androgens in our study, are currently under investigation. Nifedipine, as well as other 311 
Ca2+ channel blockers, can cross the placenta and elicit adverse effects upon the fetus (3) but the 312 
placenta is known to possess mechanisms that inhibit the transport of androgens (35). In particular, the 313 
placenta can aromatise native androgens, such as T, to estrogens to protect the fetus from virilisation. 314 
A female fetus would only be in danger of virilisation if the androgen was administered during the 315 
masculinisation window, which is reported to exist during the first trimester of pregnancy (36). 316 
Conversely, animal studies have informed that maternal androgen excess is associated with the 317 
development of PCOS in the offspring (37). However, in the majority of these studies, androgen 318 
excess was achieved by a daily administration of non-aromatisable DHT in high concentrations from 319 
mid-gestation up to term (38,39). We believe it is unlikely that androgens will cause PCOS in female 320 
offspring, if given in native form for short periods to stop preterm-initiated contractions in the third 321 
trimester.  322 
Further basic understanding of the dose response and the mechanism of action of androgens on uterine 323 
contractions are required to inform the design of preclinical studies on androgens as tocolytic agents. 324 
Notably, the IC50 values generated here could help design experiments whereby administration of 325 
DHT or T to existing mouse models of PTB (40) could be used to investigate if androgens can induce 326 
uterine relaxation. Such studies could contribute to the discovery of much needed novel preterm birth 327 
therapeutics.  328 
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  453 
Figures and Table Legends 454 
Figure 1: DHT and T, but not TBSA, inhibited the contraction of human myometrial cells embedded 455 
in collagen gels. PHM1-41s were embedded in collagen gels in 24-well plates and incubated with 456 
vehicle, DHT, T or TBSA for 24 and 48 hours. Over time, vehicle gels developed a basal contraction, 457 
which manifested as a decrease in the gel area (A). The gel area at each time point was measured and 458 
reported as a percentage of the original gel area. The post treatment percentages of the original gel 459 
area were compared to those of vehicle. DHT and T (50 μM and 100 μM) incubation for 24 (B) and 48 460 
(C) hours significantly inhibited the basal contraction of PHM1-41s; *p<0.05, **p<0.01, ***p<0.001 461 
compared to vehicle (etOH), n=7 (6 replicates). TBSA treatment at 0.5 μM (0.5 μM equivalent to 462 
100 μM dose of T) did not inhibit the basal gel contraction after 24 (E) and 48 hours incubation (F); 463 
**p<0.01, ****p<0.0001, ns=non-significant compared to vehicle (etOH+PBS), n=5 (6 replicates). 464 
Silencing of AR in PHM1-41s did not prevent the effect of DHT (50 μM) on the basal contraction. 24-465 
hour (G) and 48-hour (H) incubation with DHT (50 μM) induced a significantly smaller reduction in 466 
the gel area of wt PHM1-41s, scramble miR-infected (Scr-PHM1-41s; negative control) and hAR 467 
miR-infected (hAR-PHM1-41s) cells (i.e., with knock down of the AR); ***p<0.001, ****p<0.0001 468 
comparison between vehicle and DHT groups, a=not significant: comparison with wt-PHM1-41s 469 
vehicle, b=not significant: comparison with Scr-PHM1-41s vehicle, c= not significant: comparison 470 
with wt-PHM1-41s-DHT group, d= not significant: comparison with Scr-PHM1-41s-DHT group, n=5 471 
(6 replicates). I: Viability of PHM1-41 cells post incubation with DHT and T (100 μM) for 48 hours. 472 
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PHM1-41 cells were embedded in collagen gel and treated with DHT and T. Viability assay was 473 
performed on the gels 48 hours post treatment. Treatments with DHT and T did not affect viable cell 474 
number, which manifested as no change in cell metabolic activity; ns=non-significant compared to 475 
vehicle (etOH), n=4. Cell viability data were analysed using Kruskal-Wallis with Dunn’s post-hoc 476 
test. Gel contraction data were analysed using one-way ANOVA with either Tukey’s post-hoc test (B, 477 
C, E, F) or Sidak’s multiple comparison test (G, H).  478 
Figure 2: DHT and T, but not TBSA, rapidly relaxed spontaneous contractions of myometrium 479 
obtained from LN and OB women undergoing ECS at term. A: Representative recordings show the 480 
effect of DHT, T and TBSA on stretched-induced myometrial contractions of the LN group. Each 481 
contracting LN and OB myometrial strip was incubated with either cumulative doses (10 μM-100 μM) 482 
of vehicle, DHT or T, or with a single dose of TBSA (0.5 μM equivalent to 100 μM dose of T). Each 483 
dose was applied for 30 minutes. Concentration response curves were generated to show the effect of 484 
DHT, T and vehicle on average amplitude, frequency and A.U.C. of LN (B-D) and OB (F-H) 485 
myometrial contraction. For LN, the amplitude (B) and A.U.C. (D) of contraction decreased in a dose-486 
dependent manner following either DHT or T; the decrease was significant at all doses tested. At 487 
100 μΜ dose of DHT, the amplitude of contraction reduced to 2%±2 of the original value (B) and the 488 
A.U.C. to 4.5%±2 (D). T (100 μM) also reduced the amplitude of contraction to 3.3%±1.3 (B) and the 489 
A.U.C. to 15.8%±3.8 (D).  The frequency (C) of contraction significantly decreased with the 100 μM 490 
dose of DHT and T (p<0.0001 compared to vehicle). For OB, the amplitude (F) and the A.U.C. (H) of 491 
contraction decreased in a dose-dependent manner following either DHT or T; the decrease was 492 
significant at all doses tested. At 100 μΜ, DHT reduced the amplitude to 15%±6 (F) and the A.U.C. to 493 
4.3%±2.7 (H). At the same dose, T reduced the amplitude to 11%±6.7 (F) and the A.U.C. to 10%±5 494 
(H). The frequency (G) of contraction significantly decreased only with the 100 μM dose of DHT and 495 
T (p<0.01 compared to vehicle).  Data were analysed using one-way ANOVA with Tukey’s post-hoc 496 
test. TBSA did not relax LN (E) or OB (I) human myometrial contractions; the effect of TBSA on the 497 
A.U.C. of contraction was no different to the effect induced by the vehicle (PBS). Data were analysed 498 
with two-tailed t-test; ns=non-significant, LN: n=5/1 strip per treatment, OB: n=6/1 strip per 499 
treatment.  500 
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Figure 3: DHT and T, but not TBSA, relaxed murine spontaneous uterine contractions. A: 501 
Representative recordings show the effect of DHT, T and TBSA on stretched-induced contractions of 502 
uterine horn strips. Each contracting strip was incubated with either cumulative doses (10 μM-503 
100 μM) of vehicle, DHT or T, or with a single dose of TBSA (0.5 μM). Each dose was applied for 504 
10 minutes. Concentration response curves were generated to show the effect of DHT, T and vehicle 505 
on average amplitude (B), frequency (C) and A.U.C. (D) of contraction. The amplitude (B) and 506 
A.U.C. (C) of contraction were dose-dependently decreased; the decrease was significant at all doses 507 
tested. DHT (100 μM) reduced the amplitude to 4.8%±3 (B) and the A.U.C. to 10.4%±5 (D). T (100 508 
μM) reduced the amplitude to 4.9%±3 (B) and the A.U.C to 4.8%±2.9 (D). Only the 100 μΜ dose of 509 
DHT significantly decreased the frequency of contraction (p<0.001 compared to vehicle). For T, the 510 
frequency was significantly reduced at both 80 μΜ (p<0.001 compared to vehicle) and 100 μΜ 511 
(p<0.0001 compared to vehicle) dose. Data were analysed using one-way ANOVA with Tukey’s post-512 
hoc test (n=5 mice/1 strip per treatment). E: TBSA did not inhibit murine uterine horn strip 513 
contraction; the effect of TBSA on the A.U.C. of contraction was no different to the effect induced by 514 
the vehicle (PBS). Data were analysed with two-tailed t-test; ns=non-significant, n=5 mice /1 strip per 515 
treatment.  516 
Table 1: DHT and T IC50 values were generated from the concentration response curves for 517 
amplitude and A.U.C.  518 
Figure 4: DHT treatment prevented the phosphorylation of MLC stimulated by OXT in human 519 
myometrial cells. The effect of DHT pre-treatment on OXT-stimulated contraction and OXT-520 
stimulated MLC phosphorylation was investigated. PHM1-41s cells were embedded in collagen gels 521 
and incubated with vehicle (dH2O + etOH), OXT (100 nΜ), DHT (50 μM) or OXT+DHT for 24 hours 522 
and 48 hours (A). The gel area was measured and reported as a percentage of the original gel area (0 523 
hour time point). The OXT gel area was significantly smaller when compared to the vehicle gel area, 524 
however co-treatment with DHT+OXT prevented the OXT alone-induced effect on the gel area at 24 525 
(B) and 48 hours (C); ***p<0.001, ****p<0.0001 comparison between OXT and vehicle, ##p<0.01, 526 
####p<0.0001 comparison between OXT and OXT+DHT, n=5 (6 replicates). D: PHM1-41s were 527 
seeded into 96-well plates and either directly exposed to acute (30 seconds) treatment with vehicle 528 
 19 
(H2O) or OXT (100 nM), or initially pre-treated (15 minutes) with vehicle (etOH) or DHT (50 μM) 529 
and then stimulated with acute OXT. E: The concentration of PMLC was significantly higher in the 530 
wells following acute OXT compared to the PMLC in the wells treated with the acute vehicle; 531 
###p<0.001, n=5 (6 replicates). The concentration of PMLC in the vehicle pre-treated cells was higher 532 
compared to the concentration of PMLC in the DHT pre-treated cells when both were exposed to 533 
acute OXT; *p<0.05, n=5 (triplicate). F: PHM1-41 cells were either directly exposed to acute vehicle 534 
(H2O) or OXT (100 nM) or first pre-treated (15 minutes) with vehicle (DMSO) or Nifedipine (50 μM) 535 
and then exposed to acute OXT. G: The concentration of PMLC in the DMSO pre-treated cells was 536 
higher compared to the concentration of PMLC in the Nifedipine pre-treated cells when both were 537 
exposed to acute OXT; ####p<0.0001 comparison between acute OXT and acute vehicle, **p<0.01 538 
comparison between Nifedipine+OXT and vehicle+OXT, n=5 (triplicate). Data were analysed using 539 
one-way ANOVA with Tukey’s post-hoc test. 540 
Figure 5: DHT treatment prevented the rapid increase in [Ca2+] concentration stimulated by OXT in 541 
human myometrial cells. A: Cells were seeded into 96-well plates and either not treated or treated with 542 
vehicle (etOH) or DHT (10 minutes) and then injected with OXT (10 nM). The injection of OXT to 543 
untreated wells rapidly increased the concentration of [Ca2+] above baseline (red plot). The DHT pre-544 
treatment (10 minutes) significantly reduced the response to OXT injection. OXT injection to vehicle 545 
(etOH) pre-treated wells increased the concentration of [Ca2+] above baseline significantly more than 546 
to DHT (B: 300 nM, C: 800 nM, D: 50 μM) pre-treated wells; *p<0.05, **p<0.01, ****p<0.0001 547 
comparison between the groups vehicle (etOH)+OXT and DHT+OXT, ###p<0.001, ####p<0.0001 548 
comparison between the groups vehicle (H2O) and OXT, n=6 (4 replicates). Data were analysed using 549 
one-way ANOVA with Tukey’s post-hoc test.  550 
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